The approval of a new drug by a regulatory body like the European Commission often leads to increased sales and revenues for the company that developed the drug. This is because the approval allows the company to market and sell the drug in the region. In this case, J&J's Talvey has been approved for the treatment of patients with relapsed and refractory multiple myeloma, a condition for which there is a significant demand for effective treatments. Therefore, this approval could potentially boost J&J's revenues and market presence in Europe.